Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been given a consensus recommendation of “Hold” by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $5.4286.

GOSS has been the subject of several recent analyst reports. HC Wainwright decreased their price objective on shares of Gossamer Bio from $10.00 to $5.00 and set a “buy” rating for the company in a report on Friday, March 6th. Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a report on Tuesday, February 24th. Barclays lowered shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a research report on Tuesday, February 24th. Cantor Fitzgerald restated a “neutral” rating on shares of Gossamer Bio in a report on Monday, March 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd.

Institutional Trading of Gossamer Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MB Generational Wealth LLC bought a new stake in shares of Gossamer Bio in the third quarter valued at approximately $3,721,000. Corient Private Wealth LLC grew its stake in shares of Gossamer Bio by 8.9% in the second quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock worth $4,543,000 after acquiring an additional 302,200 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in Gossamer Bio during the second quarter worth $53,000. AXQ Capital LP acquired a new position in Gossamer Bio during the 3rd quarter valued at $122,000. Finally, Jones Financial Companies Lllp raised its stake in Gossamer Bio by 136.7% during the 3rd quarter. Jones Financial Companies Lllp now owns 17,360 shares of the company’s stock valued at $47,000 after purchasing an additional 10,027 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

GOSS opened at $0.35 on Friday. The firm has a market cap of $81.32 million, a P/E ratio of -0.46 and a beta of 2.08. The business has a 50 day moving average price of $1.43 and a 200 day moving average price of $2.36. Gossamer Bio has a twelve month low of $0.32 and a twelve month high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Gossamer Bio had a negative net margin of 351.49% and a negative return on equity of 1,774.72%. The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $7.53 million. As a group, analysts anticipate that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.